Co-Diagnostics (CODX) Tops Q3 EPS by 17c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts CODX Hot Sheet
Join SI Premium – FREE
Co-Diagnostics (NASDAQ: CODX) reported Q3 EPS of $0.38, $0.17 better than the analyst estimate of $0.21. Revenue for the quarter came in at $30.1 million versus the consensus estimate of $24.32 million.
GUIDANCE:
Co-Diagnostics sees FY2021 EPS of $1.07-$1.16, versus the consensus of $0.98. Co-Diagnostics sees FY2021 revenue of $96-100 million, versus the consensus of $95.2 million.
For earnings history and earnings-related data on Co-Diagnostics (CODX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- Top restaurant stocks to watch, according to Raymond James
- SLM (SLM) Misses Q3 EPS by 36c; lowers guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
